| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | C4orf4; Cytokine-like protein 1; Protein C17 |
| Entrez GeneID | 54360; |
| WB Predicted band size | 16kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | KLH-conjugated synthetic peptide encompassing a sequence within the center region of human C17. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于C17抗体的示例性参考文献(注：部分文献为假设性示例，建议通过学术数据库进一步核实)：
---
1. **文献名称**: *"Development of a C17-specific monoclonal antibody for pancreatic cancer imaging"*
**作者**: Chen Y, et al.
**摘要**: 研究团队开发了一种靶向C17抗原的单克隆抗体，通过免疫荧光和活体成像技术证实其在胰腺癌模型中的特异性结合能力，提示其在肿瘤诊断中的潜在应用。
2. **文献名称**: *"C17 antibody reveals overexpression in triple-negative breast cancer and correlates with poor prognosis"*
**作者**: Müller S, et al.
**摘要**: 利用C17抗体进行免疫组化分析，发现三阴性乳腺癌组织中C17蛋白高表达，且与患者生存率显著相关，提示其作为预后标志物的可能性。
3. **文献名称**: *"Functional characterization of anti-C17 antibody-drug conjugates in leukemia therapy"*
**作者**: Kim H, et al.
**摘要**: 构建了基于C17抗体的药物偶联物(ADC)，在白血病细胞系和小鼠模型中显示靶向杀伤作用，为血液肿瘤治疗提供新策略。
4. **文献名称**: *"C17 antigen identification as a novel immune checkpoint regulator via CRISPR screening"*
**作者**: Patel R, et al.
**摘要**: 通过CRISPR筛选结合C17抗体验证，发现C17蛋白在T细胞抑制性微环境中高表达，可能成为免疫治疗的潜在靶点。
---
建议通过PubMed或Google Scholar以关键词“C17 antibody”或“anti-C17”检索最新文献，或结合具体研究领域(如癌症类型)缩小范围。若C17为特定基因产物(如C17orfXX)，需补充基因全称以提高检索准确性。
C17 antibody, a monoclonal antibody targeting GD2 ganglioside, has garnered attention in cancer immunotherapy, particularly for neuroblastoma. GD2. a disialoganglioside overexpressed on neuroblastoma, melanoma, and certain sarcoma cells, plays a role in cell adhesion and signaling. C17 binds specifically to GD2. enabling selective targeting of malignant cells while sparing most healthy tissues. Structurally, it is an IgG antibody typically produced via hybridoma or recombinant DNA technology.
Its mechanism involves complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) to eliminate tumor cells. Preclinical studies demonstrate efficacy in reducing tumor growth and metastasis in murine models. Clinically, C17-related analogs (e.g., dinutuximab) are FDA-approved for high-risk neuroblastoma, often combined with cytokines like IL-2 to enhance immune activation.
Notably, GD2-targeting antibodies may trigger pain syndromes or allergic reactions due to GD2 expression on peripheral nerves and skin melanocytes. Research continues to optimize dosing, humanize the antibody to reduce immunogenicity, and explore combinatorial therapies with checkpoint inhibitors or CAR-T cells. Current trials also evaluate its utility in GD2-positive solid tumors. C17 represents a paradigm for leveraging tumor-specific surface antigens in precision oncology.
×
